What is the main function of avatrombopag?

Avatrombopag (Avatrombopag, trade name: Sucoxin, is an oral second-generation thrombopoietin receptor agonist (TPO-RA). This innovative drug was first developed by the American company AkaRx and later introduced to the Chinese market by Fosun Pharma, filling the domestic drug gap in the treatment of thrombocytopenia related to chronic liver disease (CLD). As a non-peptide small molecule compound, avatrombopag can interact with the transmembrane domain of the human TPO receptor, initiate a signaling cascade, stimulate the proliferation and differentiation of megakaryocytes in the bone marrow, and thereby increase platelet production.

The main benefit of avatrombopag is its ability to significantly increase platelet counts, which is important in the treatment of thrombocytopenia. Thrombocytopenia is one of the common complications in patients with chronic liver disease. Up to 78% of patients with cirrhosis are accompanied by varying degrees of thrombocytopenia. When patients with chronic liver disease are combined with thrombocytopenia, their risk of bleeding during surgical treatment will be significantly increased, which may cause a series of clinical invasive examinations and treatments to be unable to be performed normally. Avatrombopag increases platelet production by stimulating megakaryocytes in the bone marrow, thereby effectively reducing the risk of bleeding and providing a treatment option for patients with thrombocytopenia who require surgery or other invasive tests.

Avatrombopag is not only suitable for adult patients with thrombocytopenia associated with chronic liver disease, but also shows therapeutic potential in the fields of thrombocytopenia induced by tumor chemotherapy (CIT) and immune thrombocytopenia (ITP). In clinical studies, avatrombopag demonstrated significant efficacy, with most patients achieving platelet counts of at least 50,000/µL on day 8 of treatment and maintaining platelet counts within the target range during the 6-month treatment period.

However, avatropopag is not perfect. Some patients may experience side effects such as headache, nasopharyngitis, nausea, and a few patients may also experience serious side effects such as allergic reactions, hyponatremia, peripheral edema, and thrombosis. Therefore, when using avatrombopag, you need to strictly follow the doctor's instructions, pay attention to the drug reaction, and promptly stop the drug and seek medical treatment when adverse reactions occur.

Avatrombopag has been officially launched in China, and the drug has been included in the scope of medical insurance reimbursement. On the market, patients can choose the original research version or the domestic imitation version, and the specifications are unified as 20mg*15 tablets/box. After reimbursement, the price of the original research version of the drug is about 4,000 yuan, and the domestic generic version is also over 3,000 yuan. It is worth mentioning that there are low-priced imitation versions in overseas markets. 28 pieces only cost about 600 yuan, and the prices vary greatly.

In summary, avatrombopag, as a new oralTPO receptor agonist, has significant advantages and effects in the treatment of thrombocytopenia. Despite some shortcomings, it plays a positive role in clinical treatment and brings new treatment hope to patients with thrombocytopenia.